| Identification | Back Directory | [Name]
ZK824859 | [CAS]
2254001-81-3 | [Synonyms]
CS-2839
ZK824859
ZK824190
ZK824859;ZK-824859;ZK 824859;2254001-81-3
Butanoic acid, 2-[[6-[[3'-(aminomethyl)[1,1'-biphenyl]-3-yl]oxy]-3,5-difluoro-2-pyridinyl]oxy]-, (2R)- | [Molecular Formula]
C22H20F2N2O4 | [MDL Number]
MFCD32200352 | [MOL File]
2254001-81-3.mol | [Molecular Weight]
414.4 |
| Hazard Information | Back Directory | [Uses]
ZK824190 is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC50s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively[1]. | [in vivo]
ZK824190 (2?mg/kg; PO) exhibits a relatively high oral availability and a moderate half time (T1/2=2.8 h)[1]. | Animal Model: | Rats with experimental autoimmune encephalomyelitis (EAE) model[1] | | Dosage: | 2?mg/kg (Pharmacokinetic Analysis) | | Administration: | PO | | Result: | Oral availability F?=?55%; Cmax=?0.64?g/mL and AUC?=?2.2?h*g/mL; T1/2=2.8 h. |
| [References]
[1] Islam I, et al. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. Bioorg Med Chem Lett. 2018 Nov 1;28(20):3372-3375. DOI:10.1016/j.bmcl.2018.09.001 |
|
| Company Name: |
Cckinase, Inc.
|
| Tel: |
+1 (732)236-3202 |
| Website: |
www.cckinase.com |
|